OpGen (NASDAQ:OPGN) Given a $20.00 Price Target by Aegis Analysts
OpGen (NASDAQ:OPGN) has been assigned a $20.00 target price by Aegis in a research report issued to clients and investors on Monday, TipRanks reports. The firm presently has a “buy” rating on the medical research company’s stock. Aegis’ price target indicates a potential upside of 178.55% from the company’s previous close.
Several other equities research analysts also recently commented on the company. ValuEngine downgraded OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. HC Wainwright reissued a “buy” rating and issued a $1.50 price target on shares of OpGen in a research note on Sunday, May 19th. Finally, Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.08.
Shares of NASDAQ OPGN traded up $0.89 during mid-day trading on Monday, reaching $7.18. The company had a trading volume of 75,333 shares, compared to its average volume of 103,446. The company has a 50-day moving average price of $2.25 and a two-hundred day moving average price of $1.03. The stock has a market cap of $6.33 million, a PE ratio of -0.16 and a beta of 0.77. The company has a current ratio of 0.89, a quick ratio of 0.78 and a debt-to-equity ratio of 1.07. OpGen has a 1-year low of $4.20 and a 1-year high of $48.20.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
See Also: Bear Market – How and Why They Occur
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.